alprazolam (Xanax)

How long the trials actually ran

The longest trial behind the alprazolam approval ran 10 weeks.

The gap between how long the trials ran and how long people actually take these medications is the single most important thing on this page. It is not evidence that longer use is unsafe or ineffective. It is evidence that longer use was not what got tested.

How many Americans take alprazolam

Survey-based federal estimates, published with a lag of about two years. They count prescriptions filled, not outcomes.

12,541,989

prescriptions in the United States (2024)

3,426,968

people filling them (2024)

Prescriptions are down 57% since 2014. Whatever you decide about alprazolam, you are deciding alongside about 3,426,968 other people this year.

Source: ClinCalc DrugStats (Medical Expenditure Panel Survey (MEPS), Agency for Healthcare Research and Quality), CC BY-SA 4.0, release 2026.08.

What people report to the FDA about alprazolam

204,912

reports mentioning alprazolam, all time

144,784

filed as serious (a report-level flag covering every drug and outcome in the report)

Source: FDA Adverse Event Reporting System (FAERS), via openFDA, data through 2026-07-30.

Known interactions, from the label

The FDA label’s interactions section, verbatim. A pharmacist checking your actual medication list beats any published list — including this one.

FDA label for alprazolam, effective August 27, 2026 — DailyMed.

Who pays for alprazolam

Two claims datasets and one survey, covering different populations with different instruments — they cannot be reconciled by arithmetic, and where their sum crowds the all-payer estimate, that is a finding about the estimates rather than a percentage.

Medicare Part D

Read the under-65 group correctly before the numbers: Medicare before 65 means the disabled and dual-eligible population — among the sickest, highest-need people in the program — and reading their utilization as typical adult use would be a category error. The beneficiary total sums brand-level rows, so treat it as an upper bound on distinct people. 2,316,589 beneficiaries filled 11,707,746 claims in 2024 — 1,966,784 aged 65 and over, and 349,805 under 65.

Medicaid

At least 3,090,918 prescriptions in 2024 — a floor, because 121 of 724 national data rows are suppressed for privacy and contribute zero. Medicaid covers more children than any insurer in the country and publishes no age split — how much of this number is pediatric use is not knowable from public data.

All payers (survey estimate)

The MEPS-based estimate above puts the whole country at 12,541,989 prescriptions and 3,426,968 people in 2024. Subtracting the public programs from it would produce a number for everyone else — and we do not print that number, because subtracting a survey from claims counts manufactures precision that does not exist.

The population nobody counts

The commercially insured working-age adult — statistically, the likeliest person to be reading this page — is the one population with no public per-drug count anywhere. Private claims data exists and is sold, but nothing a patient can check is published. For children the record is thinner still: no public source counts pediatric use of alprazolam specifically; the closest the public record comes is condition-level treatment rates for children, which we have traced for one condition in how childhood ADHD got counted.

Sources: Medicare Part D Prescribers — by Geography and Drug, data.cms.gov, National rows, data year 2024 (published with ~17-month lag). Medicaid State Drug Utilization Data 2024, data.medicaid.gov, national aggregate rows. Retrieved 2026-09-01.

The approval, step by step

1. Step 1

   What the approval was actually based on

   Which studies did the FDA rely on, how long did they run, and who was in them?

   Alprazolam was significantly better than placebo at each of the evaluation periods of these 4-week studies... The effectiveness of alprazolam in the treatment of panic disorder was studied in 3 short-term, placebo-controlled studies (up to 10 weeks) in patients with diagnoses closely corresponding to DSM-III-R criteria for panic disorder.

   FDA-approved labelling, 14 CLINICAL STUDIES 14.1 Generalized Anxiety Disorder / 14.2 Panic Disorder — read the label on DailyMed

   Our reading

   Anxiety: four-week studies. Panic: three studies of up to ten weeks. This is the starkest duration gap in the whole directory — a medication whose efficacy was demonstrated over four weeks, which people are commonly prescribed for years, and whose boxed warning about physical dependence was not strengthened until 2020, thirty-nine years after approval.

2. Step 2

   The approval

   When was it approved, under what application, and by whose review?

   Approved

   October 16, 1981

   Application

   NDA018276

   Review

   STANDARD

   Original sponsor

   Upjohn

   Holds it now

   Upjohn

   Label submissions since

   40

   Source: openFDA Drugs@FDA, original application ORIG-1

3. Step 3

   What was added after it was on the market

   Which warnings arrived only after millions of people were already taking it?

   • The FDA strengthened the benzodiazepine warning in 2020

     39 years after approval

     In September 2020 the FDA required the boxed warning on every benzodiazepine to be rewritten. The wording matters: physical dependence can develop even when the medication is taken exactly as prescribed, and stopping abruptly or dropping the dose quickly can cause withdrawal reactions that include seizures and can be life-threatening.

     This is not a claim that the medication is bad or that you should stop taking it. It is the opposite. It is the reason not to stop on your own. The FDA's own instruction to prescribers is to taper gradually rather than stop, and to reassess dose and duration over time.

     Worth asking

     How long is the plan for me to be on this, what does my taper look like if we decide to come off, and how will we tell withdrawal apart from my original anxiety coming back.

     FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class — U.S. Food and Drug Administration (2020)

4. Step 4

   What independent research has found since

   What has been learned by people who were not selling it?

   • Withdrawal from these medications can take months, and NICE says so

     41 years after approval

     NICE guideline NG215 covers safe prescribing and managed withdrawal for five groups of medication: opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants. It is the closest thing there is to an official answer on how coming off actually goes.

     It states that withdrawal can be difficult and may take several months or more, that symptoms vary widely in type and severity, that they affect both physical and mental health, and that they can be delayed in onset and can persist. Two recommendations are worth quoting to a prescriber. Do not stop a medicine abruptly except in exceptional medical circumstances. And taper using a slow, stepwise reduction proportionate to the current dose, so the decrements get smaller as the dose gets lower — not a fixed cut each time.

     That last detail is the one most commonly missed. Gabapentinoids are the exception in the guideline and are reduced by a fixed amount at each step.

     Worth asking

     Can we write the taper down, what size are the steps near the end, and how long do I hold at each step before the next reduction.

     Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults (NG215) — National Institute for Health and Care Excellence (2022)

   • Pharmacological treatments in panic disorder in adults: a network meta-analysis

     42 years after approval

     Across 70 randomized trials (up to 12,310 people in the largest analysis), alprazolam was among the most effective and best-tolerated drugs for panic disorder, and one of only two that clearly reduced panic-attack frequency versus placebo, though the review judged the underlying trial quality low enough to limit confidence.

     Worth asking

     Alprazolam performs well for short-term panic relief in trials - how do we balance that against dependence risk if I end up needing treatment for months, not weeks?

     Pharmacological treatments in panic disorder in adults: a network meta-analysis — Guaiana G, et al. (2023)

   • Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study

     35 years after approval

     Following 3,434 adults aged 65+ for a mean of 7.3 years, the highest cumulative benzodiazepine users showed no increased dementia risk (hazard ratio 1.07, 95% CI 0.82 to 1.39), a result that argues against a causal benzodiazepine-dementia link.

     Worth asking

     The dementia evidence on benzodiazepines points both ways - how do you weigh it for someone my age, and does it change how long I should stay on this?

     Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study — Gray SL, et al. (2016)

   • Benzodiazepine use and risk of Alzheimer's disease: case-control study

     33 years after approval

     Comparing 1,796 older adults with Alzheimer's disease against 7,184 matched controls, past benzodiazepine use beyond 3 months was associated with roughly 1.5-times higher odds of Alzheimer's, rising to 1.8-times with longer cumulative use.

     Worth asking

     Given the debated association between long-term benzodiazepine use and dementia, does my expected duration on alprazolam keep me clearly in short-term territory?

     Benzodiazepine use and risk of Alzheimer's disease: case-control study — Billioti de Gage S, et al. (2014)

   • The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder

     30 years after approval

     Pooling 8 randomized trials (at least 631 patients), alprazolam was no more effective than other benzodiazepines for panic disorder on panic-attack frequency, anxiety scores, or the share of patients who became panic-free.

     Worth asking

     Since alprazolam isn't more effective than longer-acting benzodiazepines, would a longer-acting option with a smoother wear-off be a better fit for me?

     The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder — Moylan S, et al. (2011)

   • Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment

     7 years after approval

     In an 8-week placebo-controlled trial of 526 people with panic disorder or agoraphobia with panic attacks, 50% on alprazolam were free of panic attacks at week 4 versus 28% on placebo, with benefit appearing in the first week.

     Worth asking

     Alprazolam works fast for panic - what's our plan for how long I stay on it, and how would we eventually taper off?

     Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment — Ballenger JC, et al. (1988)

5. Step 5

   What still is not known

   Which questions you might reasonably have has nobody answered yet?

   • The trials ran four to ten weeks. Physical dependence develops within weeks of daily use. The approval period barely overlapped the window in which dependence begins.
   • There is no registration-era evidence about taking it for years, because nobody was asked to produce any.
   • What does a taper look like, and who supervises it? The label says do not stop abruptly; it does not say how to stop.